Deniz Can Guven, The Editorial Board Member in BMC Cancer, shared on X:
“Out in The Lancet Oncology in OA. The OS benefits of cancer drugs approved by surrogate endpoints.
- 38 indications with OS data after approval
- Significant OS benefit in only 32% of the indications
- Late availability of (>3 years) non-significant OS results
The value of surrogate endpoints in approvals. A double-edged sword.”
Source: Deniz Can Guven/X